Efficacy of Micafungin in Experimental Hematogenous Candida Meningoencephalitis: 1,3-946;-D-Glucan as a Surrogate Marker for Detection and Therapeutic Response.

R. PETRAITIENE1,2, V. PETRAITIS 1,2, W. HOPE 1, A. M. KELAHER 1, M. P. COTTON 1, J. E. HUGHES 1, D. MICKIENE 1,2, R. L. SCHAUFELE 1, J. BACHER 3, T. J. WALSH 1;

Author address: 

1NCI, NIH, Bethesda, MD, 2SAIC-Frederick, Inc., Frederick, MD, 3OD, ORS, NIH, Bethesda, MD.

Abstract: 

Background: Hematogenous Candida meningoencephalitis (HCME) is a common complication of candidemia in pediatric patients, particularly neonates. The role of echinocandins in treating HCME is not well understood. We, therefore, studied the efficacy of micafungin in experimental HCME in a well-established non-neutropenic rabbit model. Methods: Treatment groups consisted MFG at 0.5, 2, 4, 8, 16, 24, 32, amphotericin B at 1 mg/kg/day, or untreated controls (UC). Treatment started 48 h after the intravenous inoculation of 1x106 Candida albicans blastoconidia and continued for 7 days. Results: Despite well-established infection in cerebrum, cerebellum, choroid (102-103 CFU/g), vitreous (102-103 CFU/ml), spinal cord, and meninges (10-102 CFU/g), no organisms were recovered in CSF. There was a significant decrease of fungal burden in cerebrum and cerebellum starting at dose of 8 mg/kg (p
2006

abstract No: 

M-1743

Full conference title: 

46th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • ICAAC 46th